Apoptosis and Cancer: The Bcl-2 family of proteins

1 post / 0 new
Abcamconferences's picture
Apoptosis and Cancer: The Bcl-2 family of proteins

[url=http://www.abcam.com/go.cfm?p=2698&v=<%= abcamRecipient.intUserID %>]Apoptosis and Cancer: The Bcl-2 family of proteins[/url]
Conference June 25-26, 2009
Dartmouth College
Hanover, New Hampshire USA

Abcam's meeting on [url=http://www.abcam.com/go.cfm?p=2698&v=<%= abcamRecipient.intUserID %>]Apoptosis and Cancer: The Bcl-2 family of proteins[/url] is a great opportunity for scientists looking for the latest research showcasing the most recent breakthroughs in the study of apoptosis and cancer. For ten years and more than 20 conferences, Abcam has created a partnership with the scientific community to deliver quality meetings that present ongoing study and discoveries.

Thursday, June 25, 2009 9am-7pm
Friday, June 26, 2009 9am-5pm

Barbara Conradt (Dartmouth Medical School), Marie Hardwick (Johns Hopkins University) and Abcam, Inc.

The Bcl-2 family of proteins (Bcl-2-like proteins, Bax/Bak, BH3-only proteins):

* Regulation and role in apoptosis and tumorigenesis
* Non-apoptotic functions
* Targets for the development of cancer therapeutics

Invited speakers:
* David Vaux (La Trobe University)
BH3-only proteins: accomplices or accessories to murder?
* Nika Danial (Dana-Farber Cancer Institute)
A phospho-BAD BH3 helix selectively activate glucose metabolism
* Gordon Shore (McGill University)
Bcl-2 Inhibition for the Treatment of Cancer
* Elizabeth Jonas (Yale University)
BCL-xL in the synapse: How a mitochondrial protein regulates neuronal activity
* Richard Youle (NINDS)
Bcl-2 family proteins, apoptosis and mitochondrial morphogenesis
* Andreas Strasser (Walter & Eliza Hall Institute of Medical Research)
The role of the Bcl-2 protein family in tumorigenesis and cancer therapy
* Gerald Cohen (University of Leicester)
BCL2 inhibitors and chronic lymphocytic leukemia
* Marie Hardwick (Johns Hopkins University)
Bcl-xL regulates mitochondrial structure and function
* Saul Rosenberg (Abbott Laboratories)
Apoptosis as a therapeutic target: Inhibiting the Bcl-2 family proteins
* A. Thomas Look (Dana Farber Cancer Institute)
Chk1 suppresses a Caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2 and Caspase-3
* David Andrews (McMaster University)
Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes
* Ruth Craig (Dartmouth Medical School)
MCL1 regulation and dysregulation: How cells change their minds and how defects in this process contribute to cancer
* Alan Eastman (Dartmouth Medical School)
Bcl2 inhibitors as adjuvants to chemotherapy
* Barbara Conradt (Dartmouth Medical School)
Regulation and function of Bcl-2 family members in C. elegans

Abcam would like acknowledge the following organizations for their support of the meeting:

Norris Cotton Cancer Center


If you are interested in sponsoring or exhibiting at this meeting, please contact us for more information.

Call for papers:
Abstracts for oral presentations and posters which fit within the theme of the meeting are invited. There will be reception during the poster session to allow interactions with experts in the field. Register and submit your abstract online!

Oral abstract deadline: March 25, 2009

Poster abstract deadline: May 25, 2009

Posters will be judged. The winner will receive up to $150 off their registration for a future Abcam conference or an antibody from the Abcam catalog.

[url=http://www.abcam.com/go.cfm?p=2698&v=<%= abcamRecipient.intUserID %>]Register and submit your abstract online.[/url]